Pro Medicus (ASX:PME) share price jumps after FY21 result

Investors are buying up Pro Medicus shares today after its FY21 results…

| More on:
Medical professionals cheering good news. pro medicus

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Pro Medicus Limited (ASX: PME) share price is moving higher in early trade on Wednesday. This follows the healthcare imaging company releasing its full-year results for FY21.

At the time of writing, Pro Medicus shares are fetching $58.42 apiece, up 3.4%.

Pro Medicus share price rises on

  • Revenue from customers increased 19.5% to $67.9 million
  • Underlying profit before tax up 41% to $42.6 million compared to prior year
  • Net profit after tax attributable to shareholders increased 33.7% to $30.9 million
  • Fully franked final dividend of 8 cents per share declared, taking total dividends in FY21 to 15 cents per share
  • Record number of new contracts announced during the year
  • Company remains debt free, increasing cash and other financial assets to $61.8 million, up 42.4%

What happened in FY21 for Pro Medicus

It was another record financial year for the healthcare imaging company valued at a $5.98 billion market capitalisation. Pro Medicus was undeterred by the pandemic, delivering a significant 19.5% increase in revenue from customer contracts — taking the total to $67.9 million.

During the year, sales and implementations initiatives were at an all-time high, demonstrating the minimal impact COVID-19 restrictions had on the business. This enabled the company to cement several milestone contracts in FY21. Some of these include the $25 million 7 year deal with NYU Langone Health and the $40 million 7 year contract with Intermountain Healthcare.

Despite significant currency fluctuations, Pro Medicus’ bottom-line earnings came in at $30.9 million — representing an increase of 33.7% on the previous year.

The significant uptick in profit has allowed the board to declare a fully franked final dividend of 8 cents per share. This takes total FY21 dividends to 15 cents per share, giving an indicative yield of 0.26%.

What did management say?

Commenting on the result, Pro Medicus Chief Executive Officer Dr Sam Hupert said:

It was our most successful year by any measure. All of our key financial metrics headed in the right direction. We foreshadowed a step-up in revenue this year despite currency headwinds and lower numbers in the first quarter due to COVID restrictions and we have delivered on that. Margins continued to increase as did our cash and other financial assets. It was also our biggest year in terms of both sales and implementations, laying the
foundation for a further step-up in exam volumes in FY22

Additionally, regarding the company’s pipeline potential, Mr Hupert said:

Although we had a record year in terms of new contracts, our pipeline remains very healthy both in terms of quality and quantity. There is a good mix across the spectrum of opportunities; some cloud, some on-premise, some academic and some in the non-academic-IDN space as well as in the for-profit and private sector.

What’s next for Pro Medicus?

Pro Medicus did not specify any outlook or guidance for FY22. However, the company remains focused on expanding its customers through its pipeline. Notably, a number of opportunities are for more than one Visage product.

Additionally, Pro Medicus continues to develop products with its AI Accelerator program.

Pro Medicus share price snapshot

The Pro Medicus share price has returned an impressive 131% to shareholders over the past year. Meanwhile, the S&P/ASX 200 Index (ASX: XJO) has climbed 22.8% during the same time frame.

Based on the current share price, Pro Medicus is trading on a 194 times price-to-earnings (P/E) ratio.

Motley Fool contributor Mitchell Lawler owns shares of Pro Medicus Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Earnings Results

chicken, KFC, drumstick, fried food, junk food
Earnings Results

Collins Foods share price jumps 11% on FY22 results

This KFC restaurant operator had a strong year...

Read more »

Happy woman looking for groceries. as she watches the Coles share price and Woolworths share price on her phone
Consumer Staples & Discretionary Shares

Metcash share price storms 8% higher on FY 2022 earnings beat

Metcash had a strong 12 months...

Read more »

A young man with short black fuzzy hair and wearing a black and white striped t-shirt looks surprised at a broker's tip that Macquarie shares will rise by 30%
Earnings Results

Mesoblast share price spikes amid ‘substantial reduction in operational spend’

Mesoblast also completed the resubmission of its Biologics License Application (BLA) for remestemcel-L to the FDA last quarter.

Read more »

A doctor sits with a patient and uses a pen to point to certain parts of her mammogram scan
Earnings Results

Volpara share price up on record full-year results

ASX investors appear to be pleased with Volpara's results.

Read more »

Miner looking at his notes.
Earnings Results

Champion Iron share price falls on FY22 results

Champion Iron shares are under pressure on Thursday...

Read more »

Person with thumbs down and a red sad face poster covering the face.
Earnings Results

Here’s why the New Hope share price is tumbling 8% on Thursday

Coal prices have reached all-time highs amid Russia's war in Ukraine.

Read more »

a man sits at a bar leaning sadly on his basketball wearing a US flag sticker on his cheekbone near a half drunk beer and looking despondent as though his basketball team has just lost a game.
Earnings Results

Why is the Catapult share price tumbling 6% lower today?

Catapult shares are falling on Thursday following the release of its full-year results...

Read more »

Man with a sleep apnea mask on whilst sleeping.
Earnings Results

Fisher & Paykel share price exhales following ‘strong’ full-year results

The COVID-19 tailwind is beginning to taper off, but how did Fisher & Paykel perform in FY22?

Read more »